Tenax Therapeutics, Inc. (TENX)

3.8400 -0.0200 (-0.52%) 收市：04:00PM EDT

Tenax Therapeutics, Inc.

101 Glen Lennox Drive
Suite 300
Chapel Hill, NC 27517
United States
(919) 855-2100
https://www.tenaxthera.com

版塊: Healthcare
行業: Biotechnology
全職員工: 5

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Christopher T. Giordano	CEO, President & Director	644.77k	無	1975
Dr. Stuart Rich M.D.	Chief Medical Officer & Director	481.22k	無	1950
Mr. Lawrence R. Hoffman CPA, Esq.	Interim Chief Financial Officer	無	無	1955
Mr. Doug Randall	Executive Vice President of Commercial & Business Operations	無	無	無
Dr. Douglas Hay	Senior Vice President of Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

公司管治

截至 無 止，Tenax Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。